EP3140408A1 - Method for optimizing production of eicosapentaenoic acid (epa) ina recombinant host - Google Patents
Method for optimizing production of eicosapentaenoic acid (epa) ina recombinant hostInfo
- Publication number
- EP3140408A1 EP3140408A1 EP15789759.6A EP15789759A EP3140408A1 EP 3140408 A1 EP3140408 A1 EP 3140408A1 EP 15789759 A EP15789759 A EP 15789759A EP 3140408 A1 EP3140408 A1 EP 3140408A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- gene
- coli
- genes
- fatty acid
- epa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims abstract description 63
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title claims abstract description 63
- 229960005135 eicosapentaenoic acid Drugs 0.000 title claims abstract description 63
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 51
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 151
- 241000588724 Escherichia coli Species 0.000 claims abstract description 105
- 230000001580 bacterial effect Effects 0.000 claims abstract description 32
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 28
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 24
- 229930195729 fatty acid Natural products 0.000 claims abstract description 24
- 239000000194 fatty acid Substances 0.000 claims abstract description 24
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 23
- 241000294598 Moritella marina Species 0.000 claims abstract description 22
- 230000004133 fatty acid degradation Effects 0.000 claims abstract description 11
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 19
- 108010058432 Chaperonin 60 Proteins 0.000 claims description 19
- 101150048956 coaA gene Proteins 0.000 claims description 18
- 230000002018 overexpression Effects 0.000 claims description 18
- 108010059013 Chaperonin 10 Proteins 0.000 claims description 12
- 101100227064 Bacillus subtilis ffp gene Proteins 0.000 claims description 10
- 230000037353 metabolic pathway Effects 0.000 claims description 9
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 8
- 101150071111 FADD gene Proteins 0.000 claims description 8
- 241000519582 Pseudoalteromonas sp. Species 0.000 claims description 8
- 101150015067 fabB gene Proteins 0.000 claims description 8
- 241000929620 Moritella marina ATCC 15381 Species 0.000 claims description 7
- 108010035473 Palmitoyl-CoA Hydrolase Proteins 0.000 claims description 7
- 102000008172 Palmitoyl-CoA Hydrolase Human genes 0.000 claims description 7
- 241000863430 Shewanella Species 0.000 claims description 7
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims description 7
- 230000006652 catabolic pathway Effects 0.000 claims description 7
- 108700023175 Phosphate acetyltransferases Proteins 0.000 claims description 5
- 240000008042 Zea mays Species 0.000 claims description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 5
- 235000005822 corn Nutrition 0.000 claims description 5
- 241000519590 Pseudoalteromonas Species 0.000 claims 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 abstract description 34
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract description 20
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 abstract description 14
- 230000037361 pathway Effects 0.000 abstract description 12
- 238000003786 synthesis reaction Methods 0.000 abstract description 11
- 108050001186 Chaperonin Cpn60 Proteins 0.000 abstract description 10
- 108010001814 phosphopantetheinyl transferase Proteins 0.000 abstract description 10
- 102000004190 Enzymes Human genes 0.000 abstract description 8
- 108090000790 Enzymes Proteins 0.000 abstract description 8
- 241001275824 Shewanella pneumatophori Species 0.000 abstract description 8
- 230000001413 cellular effect Effects 0.000 abstract description 8
- 229930001119 polyketide Natural products 0.000 abstract description 8
- 150000003881 polyketide derivatives Chemical class 0.000 abstract description 8
- 230000004048 modification Effects 0.000 abstract description 7
- 238000012986 modification Methods 0.000 abstract description 7
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 abstract description 5
- 238000010367 cloning Methods 0.000 abstract description 5
- 238000012258 culturing Methods 0.000 abstract description 5
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 108010058912 Acyl-Carrier Protein S-Malonyltransferase Proteins 0.000 abstract description 3
- 230000000415 inactivating effect Effects 0.000 abstract description 3
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 42
- 108091008053 gene clusters Proteins 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 16
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 15
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 15
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 13
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 13
- 239000005516 coenzyme A Substances 0.000 description 13
- 229940093530 coenzyme a Drugs 0.000 description 13
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 13
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 108020002982 thioesterase Proteins 0.000 description 13
- 101150108780 pta gene Proteins 0.000 description 12
- 102000005488 Thioesterase Human genes 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 10
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 8
- 101150053253 pgi gene Proteins 0.000 description 8
- 101710146995 Acyl carrier protein Proteins 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- 101100447530 Dictyostelium discoideum gpi gene Proteins 0.000 description 7
- 101100120969 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) pgi1 gene Proteins 0.000 description 7
- 210000003000 inclusion body Anatomy 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000003209 gene knockout Methods 0.000 description 6
- 229940055726 pantothenic acid Drugs 0.000 description 6
- 235000019161 pantothenic acid Nutrition 0.000 description 6
- 239000011713 pantothenic acid Substances 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 108010046276 FLP recombinase Proteins 0.000 description 5
- 108020004566 Transfer RNA Proteins 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 101150016526 fadE gene Proteins 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102000052603 Chaperonins Human genes 0.000 description 4
- 101150077981 groEL gene Proteins 0.000 description 4
- 235000019692 hotdogs Nutrition 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 108700037654 Acyl carrier protein (ACP) Proteins 0.000 description 3
- 102000048456 Acyl carrier protein (ACP) Human genes 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 101100310155 Bacillus subtilis (strain 168) sfp gene Proteins 0.000 description 3
- 101100439426 Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110) groEL4 gene Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 102000004867 Hydro-Lyases Human genes 0.000 description 3
- 108090001042 Hydro-Lyases Proteins 0.000 description 3
- 101150007210 ORF6 gene Proteins 0.000 description 3
- 108010021592 Pantothenate kinase Proteins 0.000 description 3
- 102100024122 Pantothenate kinase 1 Human genes 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004136 fatty acid synthesis Effects 0.000 description 3
- 101150022010 gam gene Proteins 0.000 description 3
- 238000012224 gene deletion Methods 0.000 description 3
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 3
- 101150006844 groES gene Proteins 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 101150025220 sacB gene Proteins 0.000 description 3
- 101150056746 sfp gene Proteins 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000011675 vitamin B5 Substances 0.000 description 3
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 101000935487 Agrobacterium fabrum (strain C58 / ATCC 33970) 3-oxopimeloyl-[acyl-carrier-protein] synthase Proteins 0.000 description 2
- 101100165660 Alternaria brassicicola bsc6 gene Proteins 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 101100499295 Bacillus subtilis (strain 168) disA gene Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- 101100226894 Phomopsis amygdali PaGT gene Proteins 0.000 description 2
- 241001260361 Photobacterium profundum Species 0.000 description 2
- 101000936720 Streptococcus gordonii Accessory secretory protein Asp5 Proteins 0.000 description 2
- 229930003571 Vitamin B5 Natural products 0.000 description 2
- -1 acetyl- Co A Chemical compound 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 101150113996 bet gene Proteins 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 2
- 229950005984 cerulenin Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 108091008147 housekeeping proteins Proteins 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000013028 medium composition Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012737 microarray-based gene expression Methods 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 235000009492 vitamin B5 Nutrition 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000007702 DNA assembly Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101710198510 Enoyl-[acyl-carrier-protein] reductase [NADH] Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102100026384 L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase Human genes 0.000 description 1
- 101100309441 Lactococcus lactis subsp. lactis sacR gene Proteins 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001208362 Photobacterium profundum SS9 Species 0.000 description 1
- 108010030975 Polyketide Synthases Proteins 0.000 description 1
- 108090000951 RNA polymerase sigma 70 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002185 fatty acyl-CoAs Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 101150042777 flp gene Proteins 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000006917 intersubunit interaction Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 125000000346 malonyl group Chemical group C(CC(=O)*)(=O)* 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6432—Eicosapentaenoic acids [EPA]
Definitions
- the present invention relates, generally, to the production of Eicosapentaenoic Acid (EPA). More specifically, the present invention relates to the optimization of EPA production by cloning genes in bacterial host cells.
- EPA Eicosapentaenoic Acid
- EPA Industrial production of EPA.
- oil is extracted from fish using an organic solvent system, after which the PUFA fraction of the fish oil is concentrated or enriched. Further purification can be achieved through chromatographic methods such as thin layer chromatography, which separates the fatty acids based on the degree of unsaturation.
- chromatographic methods such as thin layer chromatography, which separates the fatty acids based on the degree of unsaturation.
- the fatty acid ethyl ester or FAEE is the preferred and most common form.
- a need therefore, exists for a method of production of EPA which does not require extraction from fish.
- a need further exists for a method of production which produces EPA from cloned genes into bacterial cells in a pure form which can be optimized for commercially viable pharmaceutical, commercial and industrial applications.
- the present invention relates to a method for optimizing of eicosapentaenoic acid (EPA) production by cloning genes into a bacterial host.
- EPA eicosapentaenoic acid
- the term "recombinant bacterial host” shall mean an organism containing DNA from different microorganisms, most of which are genes which will be expressed.
- a preferred recombinant bacterial host is Escherichia coli (E. coli) as herein described.
- a particularly suitable strain of E. coli is NEB- ⁇ , available from New England Biolabs, Inc., Ipswich, MA.
- PUFA polyunsaturated fatty acid
- E. coli strain modified for increased EPA output.
- PKS Polyketide Synthesis
- Certain modifications to the E, coli strain to increase yield include, but are not limited to: culturing considerations; inactivating the native E.
- coli genes that control fatty acid biosynthesis, fatty acid degradation and acetyl-CoA consumption; and inserting genes to augment cellular production of NADPH, acetyl- Co A, malonyl-CoA and phosphopantetheinyl transferase, and inserting chaperonin genes to allow the E, coli to grow at a normal rate at lower temperatures (i.e. 15°C as opposed to 37°C).
- the E. coli genomic changes will be made to improve the yield of EPA produced by the heterologously expressed genes.
- a method of producing eicosapentaenoic acid (EPA) in a recombinant bacterial host may include in one embodiment: a.) selecting a bacterial host including at least one biosynthetic pathway, at least one degradation pathway, and at least one metabolic pathway; then, i.) deleting the at least one biosynthetic pathway; ii.) deleting the at least one degradation pathway; and, iii.) deleting the at least one metabolic pathway; b.) inserting genes to the bacterial host selected from a group consisting of Escherichia coli panK, Bacillus subtilis sfp, Moritella marina putative thioesterase I, Moritella marina pfaE, Pseudoalteromonas sp.
- the bacterial host is Escherichia coli (E. coli).
- the recombinant host may be grown at low temperatures and may be cultured in corn steep liquor.
- the term low temperature(s) shall mean temperatures below approximately 16°C, preferably between 13°C and 16°C; and more preferably between 14°C and 15°C and most preferably at approximately 14°C and/or 15°C.
- the biosynthesis pathway is a fatty acid biosynthesis gene such as fabB;
- the degradation pathway is a fatty acid degradation gene, and most preferably fadD and fadE;
- the metabolic pathway is a phosphate acetyl transferase gene most preferably the E. coli pta gene and/or the E. coli pgi gene.
- the knockout of the E. coli pta gene may be accompanied with the over-expression of the panK gene.
- Figure 1 is a model of the ⁇ -red plasmid constructed according to the method of the present disclosure.
- Figure 2 is a model of the donor plasmid constructed according to the method of the present disclosure.
- Figure 3 is a model of the helper plasmid constructed according to the method of the present disclosure. DESCRIPTION OF THE PREFERRED EMBODIMENTS
- Modifications in the bacterial host The following describe deletions and insertions/over-expressions in the bacterial host. Laboratory strains of Escherichia coli are known for being rapid and nonfastidious growers, making it an excellent host for heterologous genes and gene products. However, without amending the host metabolism to augment recombinant gene expression, only a minimal amount of EPA is produced. The following proposed modifications, both deletions and insertions, will be pursued to increase EPA yield in recombinant E. coli cells. Certain modifications to the E. coli strain to increase yield include, but are not limited to: culturing considerations; inactivating the native E.
- E. coli genes that control fatty acid biosynthesis, fatty acid degradation and acetyl-CoA consumption; and inserting genes to augment cellular production of NADPH, acetyl-CoA, malonyl-CoA and phosphopantetheinyl transferase, and inserting chaperonin genes to allow the E. coli to grow at a normal rate at lower temperatures.
- Gene deletions/knockout First described are the E. coli genes selected for gene deletion/knockout in order to increase EPA production.
- Delete/knockout fatty acid biosynthesis pathway Host Escherichia coli cells with the fatty acid biosynthesis fabB gene knocked out are unable to produce their own unsaturated fatty acids (PUFAs) and thus accumulate higher concentrations of recombinant EPA. It is known in the art to increase EPA yield with the addition of the antibiotic cerulenin to a culture of recombinant E. coli. Cerulenin works by inhibiting the ⁇ -ketoacyl-acyl protein synthetase, the enzyme that catalyzes the condensation reaction of fatty acid biosynthesis, specifically the fabB gene. This confirms that the fabB gene should be knocked out.
- PUFAs unsaturated fatty acids
- Delete/knockout fatty acid degradation pathways Knocking out the fadD and fadE genes will also increase PUFA production by altering the initiation of the fatty acid degradation pathway.
- the fadD gene codes for the fatty acyl-CoA synthase, the first step of the ⁇ -oxidation pathway for degradation.
- the fadE gene codes for acyl-CoA dehydrogenase, the enzyme that catalyzes the beta-oxidation of the acyl-CoA that was synthesized by the fadD gene product. By knocking out these genes, the degradation pathway is turned off, which results in improved yields of total fatty acids.
- E. coli pgi and E. coli pta genes will increase PUFA production by altering the initiation of metabolic pathways.
- Knocking out the E. coli gene pgi (which codes for glucose-6-phosphate isomerase) has been shown to increase NADPH concentration and optimize product (e.g., EPA) yield.
- E. coli panK gene deletion of E. coli pta increases coenzyme-A (CoA) and acetyl-CoA production.
- the pta gene catalyzes the first step of the pathway to convert acetyl-CoA to acetate, thus the increase in acetyl-CoA, which is a substrate in the production of EPA.
- NADPH is a known reducing agent. Supplementation of recombinant E. coli cells with NADPH in the media will increase yields of heterologously produced polyunsaturated fatty acids (PUFAs), such as EPA. Because supplementation of media with NADPH would be cost prohibitive, host E. coli cells could instead be engineered by gene deletion to increase the intracellular levels of NADPH. Knocking out the E. coli gene pgi (which codes for glucose-6-phosphate isomerase) has been shown to increase NADPH concentration and optimize product (e.g., EPA) yield.
- PUFAs polyunsaturated fatty acids
- G-6-P pentose phosphate pathway
- PPP pentose phosphate pathway
- G-6-P Glucoses- phosphate
- NADPH NADPH overabundance in Apgi cells drives excessive fatty acid biosynthesis translating the redox imbalance into an imbalance in fatty acid production. This is a positive outcome, since EPA is a fatty acid. Note that when pgi is knocked out, flux through the glyoxylate shunt is increased and acetate secretion is decreased.
- the glyoxylate shunt is a variation of the tricarboxylic acid (TCA) cycle in E. coli and centers on the conversion of acetyl-CoA to succinate for the synthesis of carbohydrates. It is because of the glyoxylate shunt that Apgi cells remain viable.
- TCA tricarboxylic acid
- E. coli pta Knocking out the phosphate acetyl transferase (E. coli pta) gene will also increase PUFA production by altering a metabolic pathway.
- the deletion of the E. coli pta gene coupled with the over-expression of the panK gene increase CoA production by 313% and acetyl-CoA production by 227%.
- the pta gene catalyzes the first step of the pathway to convert acetyl-CoA to acetate, thus decreasing the acetyl-CoA pool when the pta gene product is active.
- the pta gene is inactivated, the acetyl-CoA pool is increased but the acetate pathway deletion mutants are weaker and grow slower in anaerobic conditions; thus, these cells should be grown aerobically.
- the preferred method for gene knockout is comprised of two parts: (1) Use of a web-based design tool to generate translational gene knockout sequences; and (2) insertion of genes to be over- expressed into the gene to be knocked out. Each method is described below.
- MAGE multiplex automated genome engineering
- MODEST is a web-based tool available to automatically design oligos based on desired genotypic or phenotypic changes and is available for free and is open to all users at http://modest.biosustain.dtu.dk. Bonde, M. T., lausen, M. S., Anderson, M. V, Wallin, A. I. N., Wang, H. H., & Sommer, M. O. a. (2014).
- MODEST a web-based design tool for oligonucleotkle-mediated genome engineering and recombineermg. Nucleic Acids Research, 42(Web Server issue), W408-15.
- This online tool can be used to introduce tandem stop codons in the first half of a gene sequence. By introducing three tandem stop codons, the probability of restoring gene function by reverse mutations is reduced because all of the stop codons would need to be simultaneously reverted.
- the tandem stop codons are designed to use all three types of stop codons to abolish the possibility of restoring gene function via a tRNA suppressor mutation. By localizing the mutations to the first half of the gene, the likelihood of producing a truncated protein with some residual activity is minimized.
- the MODEST web-based tool will be used to design the pgi, fabB, and pta knockout gene sequences. The E. coli genomic sequence of each of these genes will undergo recombination, using the recombineering method, to replace the wild-type pgi, fabB, and pta sequences with the MODEST-altered translational gene knockout sequence.
- the fadD gene will be knocked out using the recombineering method to insert the Pseudoalteromonas sp. PS1M3 groEL chaperonin gene and the E. coli groES chaperonin gene sequences into the E. coli genome at the fadD loci. These two gene sequences will be preceded by E. coli promoter sequences for constitutive over-expression of these chaperonin genes.
- the fadE gene will be knocked out using the recombineering method to insert a gene cluster consisting of the M. marina putative thioesterase gene, the panK gene, and the B. subtilis sfp gene into the E. coli genome at the fadE loci. These gene sequences will be preceded by promoter sequences for constitutive over-expression of the genes in this cluster.
- genes will also be added to the host genome. Some or all of these heterologous genes will be synthesized to increase their desired activity. These genes will be assembled into one or more clusters with an arabinose promoter using the Gibson Assembly method, modified Gibson Assembly method, or other similar means and inserted into the host genome using recombineering techniques. These genes include E. coli panK, Bacillus subtilis sfp, Moritella marina putative thioesterase I, Pseudoalteromonas sp. GroEL, and E. coli GroES described in greater detail below. The M. marina putative thioestersase I gene will be cloned in the same cluster with Bacillus subtilis sfp and E. colipanK.
- Shewanella pneumataphori pfaA, pfaB, pfaC, and pfaD and Moritella marina pfaE are cloned into two respective pBAD plasmids.
- the first pBAD plasmid includes Shewanella pneumataphori SCRT-2738 pfaA, pfaB, pfaC, and pfaD genes.
- the second pBAD plasmid includes the Moritella marina MP-1 pfaE gene.
- An arabinose promoter will allow for the over-expression of the genes in the clusters. This applies to the E. coli panK, and Bacillus subtilis sfp and the Moritella marina putative thioesterase I, genes. E.coli ⁇ 70 and a j2 promoters will allow for the constitutive expression of the chaperonin genes in the cluster. This applies to the Pseudoalteromonas sp. GroEL, and E. coli GroES chaperonin genes of the preferred embodiment.
- the E. coli panK gene codes for the pantothenate kinase protein. This enzyme is responsible for phosphorylating pantothenic acid (vitamin B5) to produce coenzyme-A (CoA).
- Vitamin B5 pantothenic acid
- CoA coenzyme-A
- Cellular production of EPA begins with an acetyl-CoA substrate. Both the fatty acid synthesis and the polyketide synthesis pathways utilize acetyl-CoA and malonyl-CoA as substrates, which are both derived from the cofactor coenzyme-A (or CoA).
- Pantothenic acid (vitamin B5, formerly known as vitamin B3) is phosphorylated to produce CoA.
- pantothenate kinase which is the rate-controlling step in CoA production
- pantothenic acid 5mM
- pantothenic acid 5mM
- Acetyl-CoA and malonyl-CoA are the substrates from which EPA is produced; both are derived from the phosphorylation of coenzyme-A.
- panK gene would be incorporated into ta gene cluster and inserted into the host genome.
- the concomitant pantothenic acid supplementation could be accomplished by growing the cells in corn steep liquor, which has been shown to have a high B5 vitamin content. The growing media will be discussed in greater detail below.
- Bacillus subtilis sfp Insertion/expression of Bacillus subtilis sfp in the bacterial host.
- the sfp gene from Bacillus subtilis codes for the phosphopantetheinyl transferase (PPTase) protein.
- PPTase phosphopantetheinyl transferase
- the sfp gene from Bacillus subtilis is thought to be the most tolerant in effectively modifying ACP's from all PKS (polyketide synthesis) subclasses.
- Expression of the sfp PPTase gene in either a plasmid-borne or chromosomal format has been shown to result in stoichiometric pantetheinylation of soluble PKS proteins in E. coli.
- the PPTase enzyme catalyzes the transfer of a phosphopantetheinyl group from intracellular CoASH (reduced coenzyme A) to the active site of an acyl carrier protein (ACP); this is the first step in the cellular production of fatty acids, including EPA.
- ACP acyl carrier protein
- the extent of this post- translational modification of ACP within cells controls the rate and yield of produced fatty acids.
- Cloning this heterologous gene (sfp) into E. coli cells will produce more PPTase enzyme with the goal of increasing EPA production Insertion/overexpression of Moritella Marina putative thioesterase I in the bacterial host.
- the Moritella marina gene codes for a thioesterase I protein.
- Thioesterase activity is typically required for the release of products from polyketide synthase enzymes in the production of polyunsaturated fatty acids (PUFAs).
- PUFAs polyunsaturated fatty acids
- the gene for thioesterase in deep-sea bacteria including Shewanella pneumatophori SCRC-2738, has not been found within the PUFA synthase gene cluster (pfaA-D).
- pfaA-D PUFA synthase gene cluster
- prf € that codes for a putative "hotdog" thioesterase has been identified in the PUFA synthase gene cluster of the psychrophilic marine organism Photobacterium profundum SS9.
- Thioesterases are classified into two distinct protein families: the ⁇ / ⁇ -hydrolase thioesterase and the hotdog thioesterase.
- the hotdog thioesterase was first described as a seven-stranded antiparallel ⁇ -sheet that resembles a "bun” that wraps around the five- turn a-helical "sausage".
- the hotdog thioesterases are associated with the hydrolysis of aromatic thioesters, but the P. profundum Orf6 thioesterase shows a preference for eicosapentaenoyl-CoA, which is the thioester present in the production of EPA.
- Orf6 homologs In a BLAST database search for Orf6 homologs, a similar ortholog was found in M. marina (86% identical, 0 gaps). And, like the P.
- the orf6 ortholog in M. marina is located within 1000 bases of the start of its pfaA gene. It has therefore been suggested that these thioesterases are involved in PUFA release. Because it has also been shown that, in marine bacteria, fatty acid release by a thioesterase is a limiting factor in the production of fatty acids, it is proposed that the over-expression of the orf6 ortholog of M. marina be cloned into the genome of the E. coli host cells to increase the yield of EPA produced in E. coli. Insertion/expression of GroEL and GroES genes in the bacterial host.
- the Pseudoalteromonas sp. PS1M3 GroEL and E. coli NEB 10- ⁇ GroES chaperonin genes will also be expressed in the E. coli host cells in the preferred embodiment.
- the purpose of expressing these proteins in the host cells is to enable the cells to grow well at 15°C (low temperatures).
- Presence of the cold-adapted (GroEL) chaperonin should shorten the E. coli doubling time and minimize inclusion body formation of the heterologously- produced proteins when the cells are grown at 15°C.
- the result should be the production of EPA, since the EPA-producing enzymes will be present in the active form, as opposed to the inactive, aggregated inclusion body form.
- the above described sets of individual gene sequences will be ligated together into one contiguous sequence, referred to herein as the gene cluster. This can be repeated for multiple gene clusters.
- Two gene clusters will be produced to be incorporated into the E. coli genome: one cluster for the over-expression of panK, M. marina putative thioesterase gene, and sfp and one cluster comprised of the two chaperonin genes.
- the method to be used for ligation and formation of the gene clusters was established by Daniel G. Gibson and is thus referred to as the Gibson Assembly method.
- the specific protocol used in ligating individual gene sequences into gene clusters in this project is the NEBuilder® HiFi DNA Assembly kit (New England Biolabs). The process hereafter, however, will continue being referred to as the Gibson Assembly method.
- the gene clusters produced by Gibson Assembly will be incorporated into the E. coli genome for the purpose of gene expression and, in the preferred embodiment, for the purpose of knocking out genes whose products limit EPA production (as described above).
- the method to be used for incorporating (inserting) gene clusters into genomic DNA is a form of "recombineering," This method involves the construction of three plasmids which are transformed into competent E. coli host cells: A ⁇ -red plasmid, a donor plasmid, and a helper plasmid. The composition and function of each plasmid is described below.
- the ⁇ -red plasmid constructed from pBAD, includes the phage ⁇ recombination genes, in a preferred embodiment, the gam gene, the bet gene, and the exo gene. These genes will next be described.
- a model for how recombineering occurs for the ⁇ -red plasmid is set forth in Fig. 1.
- the gam gene codes for the Gam protein. This protein prevents an E. coli nuclease, RecBCD, from degrading linear DNA fragments, allowing preservation of transformed linear DNA in vivo.
- the bet gene codes for the Bet (or Beta) protein.
- Bet is a ssDNA-binding protein that promotes annealing of two complementary DNA molecules.
- the exo gene codes for the Exo protein. This protein has 5'-to-3' dsDNA exonuclease activity.
- these latter two ⁇ -red proteins insert linear DNA (the gene cluster) into the desired target (E. coli genomic DNA in the preferred embodiment) creating a genetic recombinant.
- ⁇ -red Exo is thought to degrade linear DNA (the gene cluster) from both 5 '-ends, exposing ssDNA that is bound by ⁇ -red Beta.
- Models for how recombineering occurs propose that the single-stranded regions of the incoming linear DNA (gene cluster) bound by the Beta protein are annealed to complementary single-stranded gaps arising at the replication fork during DNA replication. Consistent with this model, an oligo that is able to anneal to the discontinuously replicated lagging strand gives a higher recombination frequency than its complementary leading strand oligo. See Fig. 1.
- I-Scel gene also included in the ⁇ -red plasmid is the Saccharomyces cerevisiae I-Scel gene, which codes for the I-Scel protein.
- This protein is an endonuclease with very high sequence specificity; it recognizes a non-symmetrical, 18-bp sequence (the I-Scel recognition site) and generates a four base pair staggered cut with 3'-OH overhangs.
- the catalytic activity of I-Scel is used to excise the gene cluster/knockout gene sequence from the donor plasmid, which includes two I-Scel recognition sites. This sequence excision from the donor plasmid makes the dsDNA gene cluster/knockout gene sequence available for insertion into the E. coli genome.
- ⁇ -red recombination proteins It is the action of the ⁇ -red recombination proteins that are then responsible for the sequence insertion into the E. coli genome.
- I-Scel recognition sites located in the ⁇ -red plasmid, which allow for self-cleavage of this plasmid.
- the purpose of cleaving the ⁇ -red plasmid is to prevent over-expression of the ⁇ -red proteins and to eliminate unnecessary plasmids from the host cells.
- the ⁇ -red plasmid also carries an antibiotic resistance gene, such as but not limited to kanamycin.
- the donor plasmid Double-stranded linear DNA— as produced in a polymerase chain reaction (PCR)— is degraded by exonucleases when transformed directly into competent E. coli cells. Therefore, a different means of introducing the gene cluster into the E. coli host cells was developed as part of the recombineering method of the present disclosure and involves the use of a donor plasmid.
- the donor plasmid shall next be described with reference to Fig. 2.
- the Gibson Assembled gene cluster, or a knockout gene sequence, pursuant to the method of the present disclosure is cloned into pBAD, the donor plasmid, which is transformed into competent E. coli host cells.
- the gene cluster is designed such that an S.
- I-Scel recognition site flanks each end of the Gibson Assembled gene cluster.
- Either a gene cluster or a knockout gene sequence is delivered into the E. coli cells via the donor plasmid. This occurs when the cluster (or knockout gene sequence) is excised out of the donor plasmid by the I-Scel endonuclease as it cleaves the flanking recognition sites.
- the donor plasmid also carries, as part of the gene cluster/knockout gene sequence, an antibiotic resistance gene, such as but not limited to chloramphenicol, which is flanked by FRT (FLP recognition target) sites.
- an antibiotic resistance gene such as but not limited to chloramphenicol, which is flanked by FRT (FLP recognition target) sites.
- the conferred antibiotic resistance allows for selection, for if recombination is successful and the gene cluster/knockout gene sequence is inserted into the E. coli genome, the cells will be resistant to that antibiotic.
- the antibiotic resistance gene can be excised by the FLP recombinase protein that cleaves and ligates at the FRT sites.
- the FLP recombinase protein is coded for by the flp gene cloned into the helper plasmid.
- the identification of recombinants is more efficient and reproducible when using sacR counter-selection.
- the sacB gene makes E. coli sensitive to sucrose; thus, plates containing sucrose can be used to select against cells containing this functioning gene. Counter-selection is used post- recombination and after screening for antibiotic resistance conferred by the antibiotic resistance gene that is incorporated via the gene cluster/knockout gene sequence into the genome. If the plasmid carrying the sacB gene was not successfully cleaved by the I- Seel endonuclease, then cells will not grow on plates containing sucrose. The sacB gene will be included in the donor plasmid and the helper plasmid.
- the helper plasmid After selection for the antibiotic resistance gene within the gene cluster/knockout gene sequence, the resistance gene will be eliminated by using a helper plasmid that expresses the FLP recombinase protein.
- the helper plasmid shall next be described with reference to Fig. 3.
- the FLP recombinase acts on FRT (FLP recognition target) sites flanking the resistance gene within the gene cluster or knockout gene sequence.
- the helper plasmid also carries an antibiotic resistance gene, such as but not limited to ampicillin. And, like the donor and ⁇ -red plasmids, the helper plasmid contains the I-Scel gene, which codes for the I-Scel protein.
- helper plasmid There are also two I-Scel recognition sites located in the helper plasmid, which allow for self-cleavage of this plasmid.
- the purpose of cleaving the helper plasmid is to prevent over-expression of the FLP recombinase protein and to eliminate unnecessary plasmids from the host cells.
- the Shewanella pneumataphori pfaA, pfaB, pfaC, and pfaD, and particularly Shewanella pneumataphori SCRT-2738 pfaA, pfaB, pfaC, and pfaD genes of the preferred embodiment can be cloned in a pBad plasmid using restriction sites Xhol and Pmel.
- the Moritella marina pfaE, and particularly Moritella marina MP-1 pfaE genes of the preferred embodiment can be cloned into a pBAD plasmid using restriction sites Xhol and Sna l.
- the Polyketide Synthesis (PKS) pathway In the cellular production of PUFAs, the polyketide synthesis pathway involves seven protein domains, coded by five genes in Shewanella pneumatophori SCRC-2738. Known to be very versatile in its products, the polyketide synthesis pathway is not fully understood and functions differently based on the organism and the end-product molecule. PKS genes of the preferred embodiment. Four polyunsaturated fatty acid (PUFA) producing genes native to the cold water Pacific bacterium Shewanella pneumatophori SCRC-2738 and one from Moritella marina MP-1 are cloned into an E. coli strain modified for increased EPA output.
- PUFA polyunsaturated fatty acid
- pfaA- ⁇ which are to be expressed in the heterologous production of EPA, are arranged consecutively in the EPA-producing gene cluster of Shewanella pneumatophori, while pfaE is cloned from Moritella marina MP-1.
- pfaA-D the protein domains have been identified as being homologous to other known PKS proteins, as well as a few fatty acid synthesis (FAS) proteins.
- FES fatty acid synthesis
- the M. marina pfaE gene is homologous to the pfaE gene of S. pneumataphori. It has been shown that the Moritella marina pfaE gene product works with the S. pneumatophori pfaA-D gene cluster product (enzymes) to produce EPA in E. coli cells.
- the pfaE gene from Moritella marina codes for 4' -phosphopantetheinyl transferase, or PPTase, which catalyzes the transfer of a phosphopantetheinyl group from intracellular CoASH (reduced coenzyme A) to the active site of an acyl carrier protein (ACP); this is the first step in the cellular production of fatty acids, including EPA. The extent of this post-translational modification of ACP within cells controls the rate and yield of produced fatty acids.
- PPTase 4-phosphopantetheinyl transferase
- ACP acyl carrier protein
- KS 3-ketoacyl-ACP synthase
- the 3-ketoacyl-ACP reductase reduces the beta ketone to a hydroxyl group, and the 3-hydroxydecanoyl- ACP dehydratase (DH) dehydrates the hydroxyl, leaving a carbon-carbon double bond. It is thought that this hydratase also has an isomerase function (DH/I) to convert the trans-double bond to a cis-conformation, which is biologically favored.
- the enoyl-ACP reductase further reduces the double bond to a fully saturated single bond, where applicable, before adding the next iterative two-carbon unit until the chain reaches twenty carbons.
- Codon bias of heterologous genes Whenever introducing genetic material into a heterologous host with the purpose of expressing those genes and increasing the yield of the protein product, codon use frequency should be considered. Codon use may be a strong predictor of gene expression. Charged transfer RNAs, or tRNAs 'loaded' with an amino acid and ready for translation, may be a limiting reactant for heterologous expression, especially during periods of amino acid starvation or high translational activity. Some tRNAs are less sensitive to starvation than others, and these will be charged at a much higher frequency than other tRNAs that code for the same amino acid. Designing the codon usage of the heterologous genes accordingly will make expression more robust.
- a useful tool for the development of sequence models is Gene Designer 2.0 available commercially from DNA 2.0, Menlo Park, CA. The DNA fragments designed by this software tool can then be ordered using Gene Designer files.
- Preferred growth conditions for the recombinant host of the present disclosure For the purpose of producing EPA with maximal yield, optimal growing conditions must be utilized. The following conditions are proposed to achieve the goal of EPA production with high yields.
- heterologous genes in E. coli often results in the production of proteins that are insoluble, inactive, or rapidly degraded. Aggregates of these proteins, known as inclusion bodies, are thought to result from the proteins' inability to fold into their native state.
- a technique to limit inclusion body formation is to grow cells at reduced temperatures. Because the optimal temperature for the psychrophilic S. pneumatophori EPA-producing enzymes is 15°C, growing the cells at a low temperature to minimize inclusion body formation is cooperatively beneficial.
- E. coli is a mesophilic organism, cultivation at reduced temperatures results in a dramatic reduction in the growth rate and, consequently, the reduced rate of the synthesis of heterologous proteins. Specifically, E.
- coli GroEL chaperonin consists of a homotetradecameric double- ring cylinder composed of ⁇ 57kDa subunits and that its co-chaperonin, GroES, consists of a homoheptameric dome-shaped ring composed of ⁇ 10kDa subunits. Also shown was that the GroEL subunit consists of an apical, an intermediate, and an equatorial domain. The apical domains form the entrance to the GroEL cavity and include the residues involved in binding to GroES and unfolded proteins. The small intermediate domain has potential hinge regions at its connection to the equatorial and apical domains.
- the equatorial domain which includes both the N- and C-termini of GroEL, contains an ATP-binding site and also most of the residues that make inter-subunit contacts. Furthermore, it was determined that the C-terminal segment of the GroEL equatorial domain plays an important role in inter-subunit interactions in GroEL assembly and that the C-terminal segment is not highly conserved. Thus, when the DNA sequence that codes for the C-terminal segment of GroEL from the cold-adapted psychrophilic bacterium Pseiidoalteromonas sp. PS1 M3 was introduced into E. coli in the form of a chimeric plasmid construct, the E. coli cells became cold-adapted.
- the expression of the cold-adapted GroEL in E. coli resulted in a shortened doubling time of the cells when grown at low temperatures.
- the groESL promoter region, groES gene, and the approximately 49 bp segment between groES and groEL will be cloned from E.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461990566P | 2014-05-08 | 2014-05-08 | |
PCT/US2015/030041 WO2015172119A1 (en) | 2014-05-08 | 2015-05-08 | Method for optimizing production of eicosapentaenoic acid (epa) ina recombinant host |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3140408A1 true EP3140408A1 (en) | 2017-03-15 |
EP3140408A4 EP3140408A4 (en) | 2018-01-03 |
Family
ID=54367292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15789759.6A Withdrawn EP3140408A4 (en) | 2014-05-08 | 2015-05-08 | Method for optimizing production of eicosapentaenoic acid (epa) ina recombinant host |
Country Status (4)
Country | Link |
---|---|
US (1) | US20150322467A1 (en) |
EP (1) | EP3140408A4 (en) |
CA (1) | CA2948896A1 (en) |
WO (1) | WO2015172119A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110551671B (en) * | 2019-09-25 | 2021-11-09 | 南京工业大学 | Surfactin producing genetic engineering bacterium and construction method and application thereof |
WO2023070027A2 (en) * | 2021-10-20 | 2023-04-27 | University Of Puerto Rico | Fatty acid production in escherichia coli |
CN114752606B (en) * | 2022-04-02 | 2023-09-26 | 中国科学院水生生物研究所 | Transcription regulator PfaR for promoting Shewanella EPA synthesis and application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3798127A (en) * | 1972-06-20 | 1974-03-19 | Fab De Antibiotice Iasi | Medium for the culture of the escherichia coli strain |
US7217856B2 (en) * | 1999-01-14 | 2007-05-15 | Martek Biosciences Corporation | PUFA polyketide synthase systems and uses thereof |
US6818752B2 (en) * | 2000-01-31 | 2004-11-16 | Biocatalytics, Inc. | Synthetic genes for enhanced expression |
US20100242345A1 (en) * | 2006-05-19 | 2010-09-30 | LS9, Inc | Production of fatty acids & derivatives thereof |
US20110111458A1 (en) * | 2008-03-18 | 2011-05-12 | Kyowa Hakko Kirin Co., Ltd. | Industrially useful microorganism |
WO2011153344A2 (en) * | 2010-06-02 | 2011-12-08 | University Of Delaware | Engineering complex microbial phenotypes with transcription enhancement |
US10131897B2 (en) * | 2014-03-03 | 2018-11-20 | Synthetics Genomics, Inc. | Molecules associated with fatty acid biosynthetic pathways and uses thereof |
-
2015
- 2015-05-08 WO PCT/US2015/030041 patent/WO2015172119A1/en active Application Filing
- 2015-05-08 US US14/708,177 patent/US20150322467A1/en not_active Abandoned
- 2015-05-08 CA CA2948896A patent/CA2948896A1/en not_active Abandoned
- 2015-05-08 EP EP15789759.6A patent/EP3140408A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP3140408A4 (en) | 2018-01-03 |
US20150322467A1 (en) | 2015-11-12 |
CA2948896A1 (en) | 2015-11-12 |
WO2015172119A1 (en) | 2015-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gemperlein et al. | Polyunsaturated fatty acid production by Yarrowia lipolytica employing designed myxobacterial PUFA synthases | |
Gemperlein et al. | Polyunsaturated fatty acid biosynthesis in myxobacteria: different PUFA synthases and their product diversity | |
Chen et al. | Transcriptome analysis reveals that up-regulation of the fatty acid synthase gene promotes the accumulation of docosahexaenoic acid in Schizochytrium sp. S056 when glycerol is used | |
JP6407228B2 (en) | A method for the control of fluxes in metabolic pathways via protease manipulation | |
Hayashi et al. | Enhanced production of polyunsaturated fatty acids by enzyme engineering of tandem acyl carrier proteins | |
US20230136909A1 (en) | Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing 3-hydroxyisobutyrate or methacrylic acid related thereto | |
Wu et al. | Construction of artificial micro-aerobic metabolism for energy-and carbon-efficient synthesis of medium chain fatty acids in Escherichia coli | |
US20230287464A1 (en) | Microorganisms and methods for the production of butadiene using acetyl-coa | |
Gemperlein et al. | Metabolic engineering of Pseudomonas putida for production of docosahexaenoic acid based on a myxobacterial PUFA synthase | |
WO2012177726A1 (en) | Microorganism for producing primary alcohols and related compounds and methods related thereto | |
JP2014526237A (en) | Formation of fatty acids and their derivatives with improved aliphatic chain length and saturation characteristics | |
Solomon et al. | Tuning primary metabolism for heterologous pathway productivity | |
Ujihara et al. | Identification of a novel type of polyunsaturated fatty acid synthase involved in arachidonic acid biosynthesis | |
US20150322467A1 (en) | Method for optimizing production of eicosapentaenoic acid (epa) in a recombinant host | |
Chai et al. | Synthetic biology toolkits and metabolic engineering applied in Corynebacterium glutamicum for biomanufacturing | |
Balzano et al. | Biosynthesis of long chain alkyl diols and long chain alkenols in Nannochloropsis spp.(Eustigmatophyceae) | |
Liu et al. | Metabolic engineering of oleaginous yeast in the lipogenic phase enhances production of nervonic acid | |
Kim et al. | Rewiring FadR regulon for the selective production of ω-hydroxy palmitic acid from glucose in Escherichia coli | |
Lee et al. | Enhanced free fatty acid production by codon-optimized Lactococcus lactis acyl-ACP thioesterase gene expression in Escherichia coli using crude glycerol | |
Dietrich et al. | Refactoring the architecture of a polyketide gene cluster enhances docosahexaenoic acid production in Yarrowia lipolytica through improved expression and genetic stability | |
KR20220085818A (en) | Microorganisms and methods for increasing cofactors | |
Jia et al. | Enhanced fatty acid storage combined with the multi-factor optimization of fermentation for high-level production of docosahexaenoic acid in Schizochytrium sp. | |
US9127298B2 (en) | Production of fatty acids by heterologous expression of gene clusters from myxobacteria | |
JP6816970B2 (en) | Polyunsaturated fatty acid polyketide synthase and its utilization | |
JP2023541809A (en) | Synthetic growth on one-carbon substrates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20161206 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20171201 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12P 1/04 20060101AFI20171128BHEP Ipc: C12P 7/64 20060101ALI20171128BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200203 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200616 |